According to a research report "Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Consumables, Instrument), Technique (Flow Cytometry, NGS, Microscopy, MS), Application (Research, Medical), End User (Pharma, Biotech, Hospitals) - Global Forecast to 2028", size is projected to reach USD 7.1 billion by 2028 from 3.5 billion in 2023, at a CAGR of 15.3% during the forecast period. Factors such as technological developments in single-cell analysis products along with increased R&D in the pharmaceutical and biotechnology sectors, growing emphasis on personalized treatment, growth in stem cell research, and the rising incidence of cancer are driving growth of single-cell analysis market. However, one of the main reasons impeding the expansion of this market is the high price of single-cell analysis equipment.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171955254
Browse in-depth TOC on "Single Cell Analysis Market”
257 – Tables
57 – Figures
296 – Pages
Key Player
The global single-cell analysis market is highly consolidated. Key players in the market include Becton, Dickinson and Company (US), Danaher Corporation (US), Merck KGAA (Germany), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), 10x Genomics (US), Promega Corporation (US), Illumina, Inc. (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies, Inc. (US), Tecan Group Ltd. (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), Fluxion Biosciences (US), Menarini Silicon Biosystems, Inc. (Italy), bioMérieux SA (France), Oxford Nanopore Technologies (UK), Cytek Biosciences (US), Corning Incorporated (US), Apogee Flow Systems Ltd. (UK), NanoCellect Biomedical (US), Rarecyte Inc (US), and On-chip Biotechnologies Co., Ltd. (Japan). The key players in this market are increasingly focusing on strategic expansions, partnerships, to expand their manufacturing capabilities and increase market presence.
Drivers: Growing prevalence of cancer
One of the most important application areas of single-cell analysis is cancer genomics. According to GLOBOCAN, the number of cancer cases will rise to approximately 30 million by 2040 from 19.3 million cases and 10 million cancer deaths in 2020. The growth in the prevalence of this disease has resulted in a need to conduct extensive research for diagnosis and treatment; single-cell analysis forms an important part of this research. The analysis of individual cells enables the correct diagnosis of diseases and monitoring of treatment efficacy. Single-cell analysis aids in the enumeration of helper T-cells, determination of DNA content, and monitoring the proliferation of tumor cells in breast cancer and other malignancies.
Restraints: High cost of single-cell analysis products
The cost of research in single-cell biology is high because of the need to maintain high-quality standards (the use of high-grade, expensive products) and comply with the guidelines set by regulatory authorities. However, research and academic laboratories find it difficult to afford such expensive instruments due to budget constraints. In addition, the maintenance costs and several other indirect expenses result in an overall increase in the total cost of ownership of these instruments. This is a major factor limiting the adoption of flow cytometers and microfluidic devices in both clinical and research applications.
Opportunities: High growth potential of single-cell sequencing
Single-cell sequencing is considered a powerful tool to identify disease-specific biomarkers to diagnose and monitor the occurrence and progress of a disease and the patient’s response to treatment. As the SCS technology provides extensive details pertaining to genetic mutations, companies are focusing on developing instruments and reagents that are suitable for single-cell sequencers. Considering the high-growth potential of this segment, several advanced SCS instruments are expected to be developed and launched in the market in the coming years.
Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=171955254
Recent Developments:
- In March 2021, Beckman Coulter (a subsidiary of Danaher Corporation) launched the CytoFLEX SRT Benchtop Sorter that features expanded laser and color options for use in labs of all sizes.
- In March 2020, Fluidigm Corporation (US) opened a new Center of Excellence (CoE) for Imaging Mass Cytometry (IMC) in Singapore, together with the Singapore Immunology Network (SIgN), part of the Agency for Science, Technology and Research.
North America was the largest regional market for single-cell analysis in 2020.
North America accounted for the largest share of 44.9% of the global single-cell analysis market in 2020. This market is expected to reach USD 2,520.2 million by 2026 from an estimated USD 1,282.2 million in 2021, at a CAGR of 14.5%. North America’s prominence in this market is mainly attributed to the presence of key market players, coupled with increasing R&D expenditure and federal funding.
Report Link: Single-cell Analysis Market
Table of Contents:
1 INTRODUCTION (Page No. - 40)
- STUDY OBJECTIVES MARKET DEFINITION
- MARKET DEFINITION
- INCLUSIONS AND EXCLUSIONS
- MARKETS COVERED
FIGURE 1 SINGLE CELL ANALYSIS INDUSTRY SEGMENTATION
- RESEARCH METHODOLOGY (Page No. - 46)
- RESEARCH APPROACH
- MARKET DATA ESTIMATION
- MARKET ESTIMATION METHODOLOGY
- GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
- EXECUTIVE SUMMARY (Page No. - 56)
- PREMIUM INSIGHTS (Page No. - 61)
- SINGLE CELL ANALYSIS MARKET OVERVIEW
- 2 NORTH AMERICA: SINGLE-CELL ANALYSIS MARKET SHARE, BY PRODUCT & COUNTRY
- SINGLE-CELL ANALYSIS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
- SINGLE-CELL ANALYSIS MARKET SHARE, BY END USER, 2020
- SINGLE-CELL ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- MARKET OVERVIEW (Page No. - 64)
- INTRODUCTION
- MARKET DYNAMICS
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/single-cell-analysis-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/single-cell-analysis.asp
Related Reports:
